InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.70
(
-0.11%
)
Bitcoin
64,814.22
(
-0.50%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: DewDiligence post# 143772

Wednesday, 06/13/2012 1:13:23 PM

Wednesday, June 13, 2012 1:13:23 PM

Post# of 252255
Well the post posited that Roche purchasing this company would be a major negative for REGN. To my mind that would only be the case if Roche managed somehow to prevent the use of the new drug with Eylea. It is true that Lucentis/Fovista has a head start by virtue of being tested together, but long term Eylea/Fovista should work just as well if they can run the appropriate trials.

Peter

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up